SATL1
Spermidine/spermine N(1)-acetyltransferase-like protein 1
Also known as: SATL1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86VE3
- Gene
- SATL1
- Ensembl
- ENSG00000184788
- Chromosome
- X
- Canonical length
- 695 aa
- Protein class
- Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
Predicted to enable spermidine binding activity. Predicted to be involved in spermidine acetylation. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
695 residues, UniProt reviewed canonical sequence.
>Q86VE3|SATL1
1 MNQSGTNQSS LSDSNQAGIN QPSTNSLGMN QMDMNQGSAS LYEMNQVDMK QPSMSQAGMR
61 QSGTNLPDIN QPDMKQPDTW QLGRSQPGML QQELSQLVLS KAGISQPDPS QPGPSQSGPS
121 QSRMRQIGTN QSGMSQPVMQ QLDSQSGGSQ PSMRQVGTSQ LGTSQIGMSQ PGTWQTGLSQ
181 PVLRQPNMSP PGMWQPGVQQ PGISQQVPSH PDMSQPGMSQ QVPSQPGIRQ PDTSQSCKNQ
241 TDMSQPDANQ SSLSDSNQTG IIQPSPSLLG MNQMDMNQWS ASLYEMNQVD MKQPSMSQAG
301 MRQSGTNLPD INQPGMKQPG TWQLGRSQPG MWPQSLSELV LSEASISQPG PPQRAPSQSG
361 PRQSSTSQAG TNQSGISQPV MWQLDMRQSG GSQPSMRQVG TSQSGTSQIG MSQPGTWQTG
421 LSQPVPRQPN KSPPGMWQRG MWQPGMSQQV PSQLGMRQPG TSQSSKNQTG MSHPGRGQPG
481 IWEPGPSQPG LSQQDLNQLV LSQPGLSQPG RSQPSVSQMG MRQTSMDYFQ IRHAEAGDCP
541 EILRLIKELA ACENMLDAME LTAADLLRDG FGDNPLFYCL IAEVNDQQKP SGKLTVGFAM
601 YYFTYDSWTG KVLYLEDFYV TQAYQGLGIG AEMLKRLSQI AITTQCNCMH FLVVIWNQAS
661 INYYTSRGAL DLSSEEGWHL FRFNREELLD MAWEELocalizationUniProt · AlphaFold · HPA
Whether an antibody against SATL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.64
- Highest tissue expression
- 0.9 nTPM
Expression across tissuesHPA
Tissue
- testis: 0.9 nTPM
- cerebral cortex: 0.4 nTPM
- adrenal gland: 0.3 nTPM
- basal ganglia: 0.3 nTPM
- amygdala: 0.2 nTPM
- hippocampal formation: 0.2 nTPM
Single-cell type
- late spermatids: 29 nCPM
- sertoli cells: 28 nCPM
- cardiomyocytes: 21 nCPM
- lactotrophs: 17 nCPM
- bergmann glia: 16 nCPM
- retinal amacrine cells: 15 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 1.6 nTPM
- basal ganglia: 1.3 nTPM
- white matter: 1.3 nTPM
- amygdala: 0.9 nTPM
- hypothalamus: 0.9 nTPM
- hippocampal formation: 0.8 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.64
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.17
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SATL1 as an antibody target. Whether an autoantibody or antibody against SATL1 could matter depends on whether native SATL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SATL1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SATL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...